SK Biopharm is set to showcase its AI-driven drug development strategies at the upcoming BIO USA 2026 event, aiming to foster collaborations with global pharmaceutical companies and investors.
The company announced its participation in the Biotechnology Innovation Organization International Convention, taking place in San Diego from June 22 to 25. This year marks SK Biopharm's second consecutive independent booth at the event, strategically positioned in the ‘Digital Health and AI Zone,’ which focuses on the integration of digital health and AI technologies within the pharmaceutical sector.
At BIO USA, SK Biopharm intends to engage in one-on-one meetings to explore potential collaborations across various domains, including research and development and business growth. The company will highlight its comprehensive AI utilization strategy under the slogan ‘SK, AI for Every Patient,’ emphasizing novel drug discovery, digital transformation, and patient-centric platforms. These initiatives aim to enhance productivity and foster data-driven decision-making in drug development.
CEO Lee Donghun emphasized the significance of this event for expanding collaboration opportunities and introducing SK Biopharm's R&D capabilities. The company is committed to leveraging AI to improve operational efficiency and provide innovative therapeutic solutions to patients globally. This focus on AI integration positions SK Biopharm as a forward-thinking player in the evolving landscape of life sciences.